crwefinancelogo2

signup3m

PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to provide an update on the Company’s successful international approach to commercializing its proprietary and patent pending stem cell technologies.

Mr. Michael Cohen, Chairman and CEO of Proteonomix, noted:

1. In the past few months the Company has undertaken an intensive international effort to establish strategic joint ventures in several European and Mid-Eastern nations for our Proteonomix Regenerative Translational Medicine Institute, Inc. We may be able to finalize the terms and conditions on at least one agreement arising from this initiative in the short term.

As a reminder, PROT’s mission is to translate the most promising internal and external stem cell biology and cellular therapy to clinical applications of regenerative medicine. We have had discussions regarding the creation of clinics in more one than one country and we believe that we may be able to eventually open such regenerative medicine clinics in Europe and/or the Middle East in the coming year.

2. Of course, we intend that such clinics will operate under the strictest cGMP guidelines allowing us to use the clinical information generated for our future discussions with the FDA, which would be helpful in pursuing the more arduous process for eventually establishing regenerative medicine clinics in the United States.

PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products.

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. LIFE systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of .3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference.

LIFE reported their results for its second quarter ending June 30, 2010. Their Non-GAAP revenue for the second quarter was 6 million, an increase of 8 percent over the 9 million reported for the second quarter of 2009. Excluding the impact of currency and prior acquisitions and divestitures, organic revenue for the quarter grew 6 percent over the same period in the previous year.

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)